In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
|Podcasts|July 18, 2019
Navigating New Developments in NSCLC in Dallas
Author(s)Onclive Team
We traveled to Dallas, Texas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from Baylor Scott and White Health System faculty.
Advertisement
We recently traveled to Dallas, Texas for a State of the Science Summit™ on Non—Small Cell Lung Cancer. At the meeting, faculty from Baylor Scott and White Health System highlighted headway made in the treatment landscapes of non–small cell lung cancer according to histology, stage, and treatment intervention, the likes of which now include immunotherapy, targeted therapy, and chemotherapy.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.
Advertisement
Advertisement
Trending on OncLive
1
Revisit Every OncLive On Air Episode From June 2026
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
5